Supernus Pharmaceuticals | SUPN - Operating Expenses


Supernus Pharmaceuticals reported $1.08B in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Abbott USD 9.31B 104M Mar/2026
ANI Pharmaceuticals USD 562.3M 344.37M Mar/2026
Aurora Cannabis CAD 48.04M 81.94M Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Canopy Growth CAD 98.72M 11.51M Mar/2026
Cara Therapeutics USD 5.94M 983K Sep/2025
Corcept Therapeutics USD 214.5M 16.87M Mar/2026
Eisai JPY 215.74B 15.84B Mar/2026
Eli Lilly USD 10.02B 285M Mar/2026
Novo Nordisk DKK 37.21B 9.56B Mar/2026
Pacira USD 172.75M 20.93M Mar/2026
Perrigo USD 935.6M 89.6M Mar/2026
Pfizer USD 90.1B 77.19B Mar/2026
Supernus Pharmaceuticals USD 1.08B 879.06M Mar/2026
United Therapeutics USD 5.9B 5.1B Mar/2026
Xeris Pharmaceuticals USD 75.21M 6.18M Mar/2026